DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 204515
NDA 204515 describes AMMONIA N 13, which is a drug marketed by 3d Imaging Drug, Biomedcl Res Fdn, Brigham Womens Hosp, Cardinal Health 414, Central Radiopharm, Essential Isotopes, Feinstein, Gen Hosp, Global Isotopes Llc, Houston Cyclotron, Johns Hopkins Univ, Kreitchman Pet Ctr, Mcprf, Midwest Medcl, Mips Crf, Ncm Usa Bronx Llc, Petnet, Precision Nuclear, Shertech Labs Llc, Sofie, Spectron Mrc Llc, Ucla Biomedical, Ucsf Rodiopharm, Univ Tx Md Anderson, Wa Univ Sch Med, and Wi Medcl Cyclotron, and is included in twenty-six NDAs. It is available from twenty-one suppliers. Additional details are available on the AMMONIA N 13 profile page.
The generic ingredient in AMMONIA N 13 is ammonia n-13. There are two drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ammonia n-13 profile page.
The generic ingredient in AMMONIA N 13 is ammonia n-13. There are two drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ammonia n-13 profile page.
Summary for 204515
| Tradename: | AMMONIA N 13 |
| Applicant: | Ncm Usa Bronx Llc |
| Ingredient: | ammonia n-13 |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 204515
| Mechanism of Action | Radiopharmaceutical Activity |
Suppliers and Packaging for NDA: 204515
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| AMMONIA N 13 | ammonia n-13 | INJECTABLE;INTRAVENOUS | 204515 | ANDA | NCM USA Bronx LLC | 24445-643 | 24445-643-30 | 30 mL in 1 VIAL, GLASS (24445-643-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 3.75-260mCi/mL | ||||
| Approval Date: | Feb 4, 2015 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
